These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24215309)

  • 1. Diabetes, cancer and treatment - a mini-review.
    Vestergaard P; Starup-Linde J
    Curr Drug Saf; 2013 Nov; 8(5):292-5. PubMed ID: 24215309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.
    Bronsveld HK; ter Braak B; Karlstad Ø; Vestergaard P; Starup-Linde J; Bazelier MT; De Bruin ML; de Boer A; Siezen CL; van de Water B; van der Laan JW; Schmidt MK
    Breast Cancer Res; 2015 Aug; 17(1):100. PubMed ID: 26242987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulins for type 2 diabetes.
    Med Lett Drugs Ther; 2019 May; 61(1571):65-68. PubMed ID: 31169803
    [No Abstract]   [Full Text] [Related]  

  • 6. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on insulin analogues.
    Drug Ther Bull; 2004 Oct; 42(10):77-80. PubMed ID: 15491022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine (Lantus) and cancer risk.
    Med Lett Drugs Ther; 2009 Aug; 51(1319):67-8. PubMed ID: 19696708
    [No Abstract]   [Full Text] [Related]  

  • 10. Insulin analogues in pregnancy and specific congenital anomalies: a literature review.
    de Jong J; Garne E; Wender-Ozegowska E; Morgan M; de Jong-van den Berg LT; Wang H
    Diabetes Metab Res Rev; 2016 May; 32(4):366-75. PubMed ID: 26431249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded table: some available insulins for type 2 diabetes.
    Med Lett Drugs Ther; 2019 May; 61(1571):e73-e77. PubMed ID: 31169807
    [No Abstract]   [Full Text] [Related]  

  • 13. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis.
    Starup-Linde J; Karlstad O; Eriksen SA; Vestergaard P; Bronsveld HK; de Vries F; Andersen M; Auvinen A; Haukka J; Hjellvik V; Bazelier MT; Boer Ad; Furu K; De Bruin ML
    Curr Drug Saf; 2013 Nov; 8(5):296-332. PubMed ID: 24215312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
    Duckworth W; Davis SN
    J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues.
    Kamal AD; Bain SC
    Expert Opin Drug Saf; 2007 Jan; 6(1):5-7. PubMed ID: 17181446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.